Bloodstream Infection Clinical Trial
Official title:
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteremia: a Multicenter, Randomized Clinical Trial (SHORTEN-2) With a DOOR / RADAR Analysis
Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the superiority of antibiotics with authorized indication for 7 days versus 14 days in the treatment of bloodstream infections produced by P. aeruginosa (BSI-PA).
The project is designed to determine the optimal duration of antibiotic treatment for Pseudomonas aeruginosa bacteremia, by comparing an adequate antibiotic treatment regimen of 7 days (experimental arm) with another of 14 days (control arm). The evaluation of infection recurrences, mortality, number of free days of antibiotic treatment, adverse events and superinfections are included as secondary objectives. Active antibiotic treatment will be considered any treatment with proven in vitro activity against the strain responsible for the patient's bacteremia, regardless of the administered dose. Clinical rules are included in order to stop antibiotic treatment or continuation and re-evaluation in each arm of treatment. This is a pragmatic study as the number or visits performed for the study are similar to the normal clinical follow-up for this patients. Final contact and final visit for the study will be performed at 90 days after the first positive blood culture. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Completed |
NCT02400268 -
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
|
Phase 3 | |
Recruiting |
NCT04070820 -
Combination Treatment for Enterococcus Faecalis Bacteriemia Multicenter, Observational Study"
|
||
Completed |
NCT03147807 -
BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU
|
N/A | |
Completed |
NCT05411315 -
Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment
|
N/A | |
Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
Terminated |
NCT04250168 -
Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
|
||
Terminated |
NCT04876430 -
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
|
Phase 2/Phase 3 | |
Completed |
NCT03255759 -
Actionable Results: Bloodstream Infection Molecular Assay Evaluation
|
N/A | |
Active, not recruiting |
NCT03744728 -
Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures
|
N/A | |
Terminated |
NCT00680459 -
Ethanol Locks for the Treatment of Central Venous Line Infections
|
Phase 3 | |
Recruiting |
NCT04839653 -
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
|
N/A | |
Recruiting |
NCT03896893 -
Neonatal Bacterial Colonization Study
|
N/A | |
Completed |
NCT05277350 -
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
Completed |
NCT00467272 -
Catheter Related - Gram Positive Bloodstream Infections
|
Phase 2 | |
Recruiting |
NCT04658017 -
GARNETâ„¢ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection
|
N/A | |
Completed |
NCT04710212 -
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
|
||
Not yet recruiting |
NCT06271031 -
Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection
|
||
Not yet recruiting |
NCT03991793 -
Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections
|